ESPR
Esperion Therapeutics Soars into 2026 with Momentum and a Clear Vision for the Future
Esperion Therapeutics, a leading player in the cardiometabolic disease space, has just concluded its Q4 2025 earnings conference call, and the news is nothing short of exciting. The company, led by President and CEO Sheldon Koenig, has reported a defining and transformative year that sets it up for continued success